The Journal of Pediatrics
Volume 150, Issue 4 , Pages 329-330 , April 2007

Is EGF the Holy Grail for NEC?

  • Michael Caplan, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael Caplan, MD, Evanston Hospital, Perinatal Pediatrics, 2650 Ridge Avenue, Evanston, IL 60201-1718.

References 

  1. Schmid KO. [A specially severe form of enteritis in newborn, enterocolitis ulcerosa necroticans. I. Pathological anatomy]. Z Kinderheilkd. 1952;8:114–135
  2. Quaiser K. [A specially severe form of enteritis in newborn, enterocolitis ulcerosa necroticans. II. Clinical studies]. Z Kinderheilkd. 1952;8:136–152
  3. Warner BW, Warner BB. Role of epidermal growth factor in the pathogenesis of neonatal necrotizing enterocolitis. Semin Pediatr Surg. 2005;14:175–180
  4. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 1995;376:337–341
  5. Halpern MD, Holubec H, Clark JA, Saunders TA, Williams CS, Dvorak K, et al. Epidermal growth factor reduces hepatic sequelae in experimental necrotizing enterocolitis. Biol Neonate. 2006;89:227–235
  6. Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA, et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol. 2002;282:G156–G164
  7. Clark JA, Lane RH, Maclennan NK, Holubec H, Dvorakova K, Halpern MD, et al. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G755–G762
  8. Clark JA, Doelle SM, Halpern MD, Saunders TA, Holubec H, Dvorak K, et al. Intestinal barrier failure during experimental necrotizing enterocolitis: protective effect of epidermal growth factor treatment. Am J Physiol Gastrointest Liver Physiol. 2006;291:G938–G949
  9. Helmrath MA, Shin CE, Fox JW, Erwin CR, Warner BW. Epidermal growth factor in saliva and serum of infants with necrotising enterocolitis. [letter] Lancet. 1998;351(9098):266–267
  10. Shin CE, Falcone RA, Stuart L, Erwin CR, Warner BW. Diminished epidermal growth factor levels in infants with necrotizing enterocolitis. J Pediatr Surg. 2000;35:173–176; discussion 7
  11. Warner BB, Ryan AL, Seeger K, Leonard AC, Erwin CR, Warner BW. Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. J Pediatr. 2007;150:358–363
  12. Harris MC, Costarino AT, Sullivan JS, Dulkerian S, McCawley L, Corcoran L, et al. Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr. 1994;124:105–111
  13. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr. 1990;116:960–964
  14. Amer MD, Hedlund E, Rochester J, Caplan MS. Platelet-activating factor concentration in the stool of human newborns: effects of enteral feeding and neonatal necrotizing enterocolitis. Biol Neonate. 2004;85:159–166
  15. Dimmitt RA, Glew R, Colby C, Brindle M, Skarsgard E, Moss RL. Serum cytosolic beta-glucosidase activity in a rat model of necrotizing enterocolitis. Pediatr Res. 2003;54:462–465
  16. Pourcyrous M, Korones SB, Yang W, Boulden TF, Bada HS. C-reactive protein in the diagnosis, management, and prognosis of neonatal necrotizing enterocolitis. Pediatrics. 2005;116:1064–1069
  17. Guthmann F, Borchers T, Wolfrum C, Wustrack T, Bartholomaus S, Spener F. Plasma concentration of intestinal- and liver-FABP in neonates suffering from necrotizing enterocolitis and in healthy preterm neonates. Mol Cell Biochem. 2002;239:227–234
  18. Klein RL, Novak RW, Novak PE. T-cryptantigen exposure in neonatal necrotizing enterocolitis. J Pediatr Surg. 1986;21:1155–1158
  19. Cobb BA, Carlo WA, Ambalavanan N. Gastric residuals and their relationship to necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2004;113(1 Pt 1):50–53
  20. Jilling T, Simon D, Lu J, Meng FJ, Li D, Schy R, et al. The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol. 2006;177:3273–3282
  21. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16
  22. Hamai Y, Matsumura S, Matsusaki K, Kitadai Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the 5’ untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology. 2005;72:133–138
  23. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res. 2004;64:2668–2672
  24. Ryder RW, Shelton JD, Guinan ME. Necrotizing enterocolitis: a prospective multicenter investigation. Am J Epidemiol. 1980;112:113–123
  25. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. [see comments] Lancet. 1990;336(8730):1519–1523
  26. Eibl MM, Wolf HM, Furnkranz H, Rosenkranz A. Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med. 1988;319:1–7
  27. Siu YK, Ng PC, Fung SC, Lee CH, Wong MY, Fok TF, et al. Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants. Arch Dis Child Fetal Neonatal Edition. 1998;79:F105–F109
  28. Halac E, Halac J, Begue EF, Casanas JM, Indiveri DR, Petit JF, et al. Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. J Pediatr. 1990;117(1 Pt 1):132–138
  29. Carlson SE, Montalto MB, Ponder DL, Werkman SH, Korones SB. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. Pediatr Res. 1998;44:491–498
  30. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005;115:1–4
  31. Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147:192–196
  32. Dvorak B, Fituch CC, Williams CS, Hurst NM, Schanler RJ. Increased epidermal growth factor levels in human milk of mothers with extremely premature infants. Pediatr Res. 2003;54:15–19
  33. Scott SM, Rogers C, Backstrom C. Dexamethasone therapy is associated with a rise in urinary epidermal growth factor concentrations in the preterm infant. Eur J Endocrinol. 1995;132:326–330
  34. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut. 2003;52:988–997

PII: S0022-3476(07)00097-2

doi: 10.1016/j.jpeds.2007.01.027

The Journal of Pediatrics
Volume 150, Issue 4 , Pages 329-330 , April 2007

Article Tools